EGFR and non-small cell lung carcinoma: It is also important to consider the possibilities of drug-drug interactions; however, there were no significant ones reported between capmatinib and EGFR-TKIs, such as gefitinib, which was approved by the FDA as first-line treatment of metastatic NSCLC in 2015 [35].